Is Doximity, Inc. (DOCS) Undervalued? Valuation & Fair Price
At $26.94, the frameworks are split on Doximity, Inc. today — Warren Buffett rates it Buy, Phil Town (Rule #1) rates it Avoid, and Benjamin Graham and Peter Lynch rate it Hold. Each model calculates its own fair value and margin of safety; create a free account to see the exact buy price behind every verdict.
Doximity, Inc.
DOCSHealthcare · Medical - Healthcare Information Services · NYSE
$26.94
P/E 28.1×
CEO
Jeffrey A. Tangney
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Website
www.doximity.comDoximity, Inc. provides a digital platform, hosted in the cloud, specifically designed for healthcare practitioners throughout the United States. This platform delivers a suite of specialized tools, empowering its members to connect with peers, streamline patient treatment, conduct remote consultations, access current medical information and research, and advance their professional careers. Its primary clientele consists of pharmaceutical companies and healthcare organizations. Established in 2010, the entity initially operated as 3MD Communications, Inc. before rebranding to Doximity, Inc. in June of that year. The company's corporate headquarters are situated in San Francisco, California.
Investor scorecard
How the four investors rate Doximity, Inc.
A split decision across the frameworks
Investor model analysis
Details lockedAt $26.93, 2 of 4 frameworks say Hold
Intrinsic Value (DCF)
Warren Buffett's valuation model · select an investor above to switch
Intrinsic Value
Locked — upgrade to viewBuy Below
Locked — upgrade to viewStrong Buy
Locked — upgrade to viewMargin of Safety
Locked — upgrade to viewUnlock buy targets with a free account
Get startedCreate a free account to see buy targets, full checklists & risk analysis Get started
Insider & congress activity
Are insiders buying DOCS?
Over recent SEC Form 4 filings, DOCS insiders bought $0 and sold $1.2M of stock across 14 open-market trades. Insiders sell for many reasons, but they buy for one.
| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| Sitaram SiddharthChief Accounting Officer | Sell | 2,077 | $54K | Sep 15, 2026 |
| Wampler Kira Schererdirector | Sell | 2,000 | $53K | Sep 1, 2026 |
| Wampler Kira Schererdirector | Sell | 2,000 | $50K | Aug 25, 2026 |
| Sitaram SiddharthChief Accounting Officer | Sell | 1,770 | $44K | Aug 13, 2026 |
| Cabral Timothy Sdirector | Sell | 7,500 | $293K | Aug 7, 2026 |
Members of Congress have also reported 2 trades in DOCS. See the full insider & congress timeline.
Source: SEC Form 4 filings. Open-market buys & sells only. Not investment advice.
See the interactive insider chart & every tradeScenario analysis
Bear, base & bull
Three growth assumptions, three fair values — and where today's price lands
What's working
Key strengths
Identified by Buffett framework analysis
Return on Equity
ROE Consistency
ROE Quality (Low Leverage)
Risk factors & concerns — free account
UnlockCompany financials
5-Year Financials
Income statement highlights — annual, USD
| Metric | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $645M | $570M | $475M | $419M | $344M |
| Rev. Growth | +13.1% | +20.0% | +13.5% | +22.0% | — |
| Net Income | $196M | $223M | $148M | $113M | $155M |
| Net Margin | 30.4% | 39.1% | 31.0% | 26.9% | 45.1% |
| EPS (Diluted) | $1.05 | $1.19 | $0.78 | $0.58 | $0.81 |
| Free Cash Flow | Locked — upgrade to view | Locked — upgrade to view | Locked — upgrade to view | Locked — upgrade to view | Locked — upgrade to view |
Full analysis included
See the complete picture for DOCS
Exact buy targets, margin of safety, detailed investor checklists, and risk breakdown — all frameworks, all numbers.
Free: 3 analyses/month · Pay per stock: $4.99 · Pro: $19.99/mo
More Healthcare stocks
Educational Use Only · Not Financial Advice
Analysis, scores, valuations, and buy zones are derived from publicly documented investor frameworks (Buffett, Lynch, Benjamin Graham, Phil Town) for learning purposes only. They are not recommendations from licensed financial advisors. Past performance does not guarantee future results. Prices may be delayed up to 15 minutes. Always conduct your own research before making any investment decisions.